Real-world studies have found an association between GLP-1 treatment and fewer asthma attacks in some people with metabolic disease. Possible explanations include weight loss, lower systemic inflammation and direct effects within the airways.

This episode examines the signal and its biological plausibility while keeping the limits clear: observational data cannot prove that Ozempic treats asthma, and controlled trials are needed before it changes routine care.

GLP-1 medicines are established in type 2 diabetes, but their role in type 1 diabetes is still emerging and often off-label. Early evidence suggests possible benefits for weight, glucose variability and insulin requirements in carefully selected patients.

This episode examines those findings alongside the risks of hypoglycaemia and ketoacidosis, and explains why specialist oversight, insulin adjustment and better long-term trials remain essential.

Cremation raises a surprisingly physical question: what happens to the mass of a human body? Most of it leaves as water vapour and gases, while the mineral structure of bone remains and is processed into the ashes returned to a family.

This episode follows the atoms through heat, combustion and the atmosphere, explains what cremated remains actually contain, and shows how body composition determines where the mass ultimately goes.